Skip to main content
Premium Trial:

Request an Annual Quote

Great Basin Shares Fall on Plans to Restructure Warrants

NEW YORK (GenomeWeb) - Shares of Great Basin Scientific dropped 12 percent today in morning trading on the Nasdaq on news that the molecular diagnostics firm will restructure its Series C Warrants.

The Salt Lake City-based firm has retained Roth Capital Partners as a financial advisor to assist in restructuring warrants issued as part of its recent follow-on public offering in March. Great Basis is also preparing to file a proxy statement and hold a special shareholder meeting to seek approval to effect a reverse stock split and authorize additional common shares to meet its obligation to deliver common shares under the cashless exercise provision of the Series C Warrants.

“While the recent Series C Warrant exercises have put our stock under greater than expected pressure, we remain on plan for our 2015 goals of securing 170 to 180 customers and four FDA-cleared products," Ryan Ashton, Great Basin president and CEO, said in a statement, adding that the funds raised in March are being used to expand the R&D and sales teams.

Great Basin raised $20.5 million in its March offering.

Its shares were down a penny at $.06 in mid-morning trade. Its 52-week trading range is between a low of $.05, which was reached this morning, and a high of $9.08.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.